-
1
-
-
13244297157
-
The hepatic sinusoid in aging and cirrhosis: Effects on hepatic substrate disposition and drug clearance
-
Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005;44:187-200.
-
(2005)
Clin Pharmacokinet
, vol.44
, pp. 187-200
-
-
Le Couteur, D.G.1
Fraser, R.2
Hilmer, S.3
Rivory, L.P.4
McLean, A.J.5
-
2
-
-
0032937925
-
Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers
-
Furlan V, Demirdjian S, Bourdon O et al. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther 1999;289:1169-1175.
-
(1999)
J Pharmacol Exp Ther
, vol.289
, pp. 1169-1175
-
-
Furlan, V.1
Demirdjian, S.2
Bourdon, O.3
-
4
-
-
1942421303
-
The effect of liver cirrhosis on the regulation and expression of drug metabolising enzymes
-
Elbekai RH, Korashy HM, El-kadi OS. The effect of liver cirrhosis on the regulation and expression of drug metabolising enzymes. Curr Drug Metab 2000; 5:157-167.
-
(2000)
Curr Drug Metab
, vol.5
, pp. 157-167
-
-
Elbekai, R.H.1
Korashy, H.M.2
El-kadi, O.S.3
-
5
-
-
0023179105
-
Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease?
-
Branch RA. Is there increased cerebral sensitivity to benzodiazepines in chronic liver disease?. Hepatology 1987;7: 772-776.
-
(1987)
Hepatology
, vol.7
, pp. 772-776
-
-
Branch, R.A.1
-
6
-
-
0017033747
-
Intravenous administration of diazepam in patients with chronic liver disease
-
Branch RA, Morgan MH, James J, Read AE. Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976; 17: 975-983.
-
(1976)
Gut
, vol.17
, pp. 975-983
-
-
Branch, R.A.1
Morgan, M.H.2
James, J.3
Read, A.E.4
-
7
-
-
0023255595
-
Mechanism of the excessive sedative response of cirrhotics to benzodiazepines - model experiments with triazolam
-
Bakti G, Fisch HV, Karlaganis G, Minder G, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines - model experiments with triazolam. Hepatology 1987; 7:629-638.
-
(1987)
Hepatology
, vol.7
, pp. 629-638
-
-
Bakti, G.1
Fisch, H.V.2
Karlaganis, G.3
Minder, G.4
Bircher, J.5
-
8
-
-
34548829698
-
Cholestasis and endogenous opioids - liver disease and endogenous opioid pharmacokinetics
-
Davis M. Cholestasis and endogenous opioids - liver disease and endogenous opioid pharmacokinetics. Clin Pharmacokinet 2007; 46:825-850.
-
(2007)
Clin Pharmacokinet
, vol.46
, pp. 825-850
-
-
Davis, M.1
-
9
-
-
0019407817
-
Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide
-
Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 1981;20:27-33.
-
(1981)
Eur J Clin Pharmacol
, vol.20
, pp. 27-33
-
-
Keller, E.1
Hoppe-Seyler, G.2
Mumm, R.3
Schollmeyer, P.4
-
11
-
-
0022728614
-
Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides
-
Moore RD, Smith CR, Lietman PS. Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med 1986; 80: 1093-1097.
-
(1986)
Am J Med
, vol.80
, pp. 1093-1097
-
-
Moore, R.D.1
Smith, C.R.2
Lietman, P.S.3
-
12
-
-
0021352405
-
-
Clive DM, Staff JS. Medical progress in renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-572.
-
Clive DM, Staff JS. Medical progress in renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-572.
-
-
-
-
13
-
-
0032713507
-
Effect of liver disease on pharmacokinetics - an update
-
Rodighiero V. Effect of liver disease on pharmacokinetics - an update. Clin Pharmacokinet 1999;37:399-431.
-
(1999)
Clin Pharmacokinet
, vol.37
, pp. 399-431
-
-
Rodighiero, V.1
-
14
-
-
0028857915
-
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease-an update
-
Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease-an update. Clin Pharmacokinet 1995;29:370-391.
-
(1995)
Clin Pharmacokinet
, vol.29
, pp. 370-391
-
-
Morgan, D.J.1
McLean, A.J.2
-
15
-
-
0030814596
-
Drug administration in chronic liver disease
-
Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Safety 1997;17: 47-73.
-
(1997)
Drug Safety
, vol.17
, pp. 47-73
-
-
Westphal, J.F.1
Brogard, J.M.2
-
16
-
-
0032710519
-
Antecedent liver disease and drug toxicity
-
Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-1105.
-
(1999)
J Hepatol
, vol.31
, pp. 1098-1105
-
-
Schenker, S.1
Martin, R.R.2
Hoyumpa, A.M.3
-
17
-
-
57049161412
-
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
-
Sep 2, Epub ahead of print
-
Varbeek RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 2008 Sep 2. [Epub ahead of print].
-
(2008)
Eur J Clin Pharmacol
-
-
Varbeek, R.K.1
-
18
-
-
67651139396
-
Guidance for industry: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling
-
FDA. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling. 2003http://www.fda.gov/cber/gdlns/imphep.pdf.
-
2003http
-
-
|